AVI Polymers Board Meeting on May 7, 2026 to Consider Fund Raising at ~₹500 Crore Valuation and MOA Amendments

1 min read     Updated on 04 May 2026, 03:20 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

AVI Polymers Limited has informed BSE of a Board of Directors meeting on May 7, 2026 to evaluate a fund-raising proposal at an indicative valuation of approximately ₹500 Crore through QIP, private placement, or preferential issue, along with MOA amendments to add IT, software development, and digital platform services to its business scope. The trading window remains closed from May 04, 2026 until 48 hours after the meeting concludes.

powered bylight_fuzz_icon
39433719

*this image is generated using AI for illustrative purposes only.

AVI Polymers Limited has notified BSE Limited of an upcoming Board of Directors meeting scheduled for Thursday, May 7, 2026, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will deliberate on two significant corporate proposals — a fund-raising initiative and amendments to the company's Memorandum of Association (MOA).

Fund Raising Proposal Under Consideration

The board will evaluate a proposal for raising funds through the issuance of instruments or securities via multiple permissible routes. The proposed transaction is being evaluated at an indicative valuation of approximately ₹500 Crore, subject to due diligence, approvals, and execution of definitive agreements. Key details of the fund-raising proposal are outlined below:

Parameter: Details
Meeting Date: Thursday, May 7, 2026
Indicative Valuation: Approximately ₹500 Crore
Fund Raising Modes: QIP, Private Placement, Preferential Issue, or combination thereof
Acquisition Methods: Share purchase, share swap, or other permissible methods
Regulatory Approvals: Subject to member approval at general meeting or postal ballot, and statutory/regulatory approvals

The company stated that this proposal is in line with its growth strategy to enhance operational capabilities and expand its market presence. The fund-raising is subject to such regulatory approvals as may be required, including the approval of members at a general meeting or through postal ballot.

MOA Amendment to Expand Business Scope

In addition to the fund-raising agenda, the board will also consider the addition of new objects in the Memorandum of Association. The proposed additions encompass the following business areas:

  • Information technology
  • Software development
  • System integration
  • Digital platforms
  • Allied technology services
  • Any other objects as may be decided by the board

This expansion of the MOA signals the company's intent to broaden its operational scope beyond its existing polymer-related business activities.

Trading Window Closure

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of AVI Polymers Limited shall remain closed from May 04, 2026 until the expiry of 48 hours from the conclusion of the Board meeting. The intimation was signed by Chintan Yashwantbhai Patel, Managing Director (DIN: 10774473), on May 04, 2026.

Historical Stock Returns for AVI Polymers

1 Day5 Days1 Month6 Months1 Year5 Years
+4.96%+33.84%+24.99%+57.71%+44.65%+110.02%

How might AVI Polymers' pivot into IT and digital platforms affect its core polymer business valuation and investor perception in the near term?

Which institutional investors or strategic partners are likely to participate in the QIP or preferential issue given the ₹500 Crore indicative valuation?

Could the MOA amendment signal a broader trend of traditional manufacturing companies diversifying into technology sectors to attract higher market multiples?

AVI Polymers Officially Launches Ashwini.tech Health AI Platform Under SEBI Regulation 30

3 min read     Updated on 30 Apr 2026, 12:59 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

AVI Polymers Limited has officially launched its flagship Ashwini.tech health AI platform on April 30, 2026, ahead of schedule, completing its dual-engine AI strategy alongside exceptional FY26 financial performance. The platform features comprehensive healthcare tools including OCR extraction, medical timelines, and family health records, positioning the company in the high-growth HealthTech and AgriTech markets with multiple revenue streams planned for commercialization.

powered bylight_fuzz_icon
38896819

*this image is generated using AI for illustrative purposes only.

AVI Polymers Limited has officially launched its flagship personal healthcare AI platform, Ashwini.tech (AVI Health AI), completing the foundational build-out of its dual-engine AI strategy. The announcement was made on April 30, 2026, under Regulation 30 of the SEBI (LODR) Regulations, 2015, with the platform now live and operational at ashwini.tech. This launch comes ahead of the previously targeted May 3, 2026, date and follows the company's exceptional FY26 financial performance.

Official Regulatory Announcement

The Board of Directors announced that the flagship personal-healthcare AI platform is now officially live and operational, developed by wholly-owned tech subsidiary AVI Health AI. The platform brings a paradigm shift to India's digital healthcare ecosystem, engineered specifically for India's mobile-first generation. The successful launch ahead of schedule completes the dual-tech ecosystem alongside the already live and scaling KrishiBuddy agritech platform, positioning AVI Polymers at the intersection of India's fastest-growing digital markets: AgriTech and HealthTech.

Launch Details Information
Platform Name Ashwini.tech (AVI Health AI)
Launch Date April 30, 2026
Target Date May 3, 2026
Regulatory Filing SEBI Regulation 30
Developer AVI AI Technologies Private Limited
Website ashwini.tech

FY26 Financial Performance

The company's audited financial results for the year ended March 31, 2026, demonstrate a complete business transformation. Revenue from operations expanded dramatically to ₹312.11 crore from ₹0.06 crore in FY25, while net profit after tax increased 24.9 times to ₹20.33 crore compared to ₹0.82 crore in the previous fiscal year. The company successfully completed a ₹89.99 crore rights issue during FY26, which was fully subscribed by shareholders, strengthening its balance sheet with net worth of ₹115.99 crore and cash and cash equivalents of ₹16.60 crore.

Financial Metric FY26 FY25 Growth
Revenue from Operations ₹312.11 Cr ₹0.06 Cr Complete reset
Total Income ₹312.59 Cr ₹1.38 Cr 226x
Profit Before Tax ₹27.73 Cr ₹1.09 Cr 25.4x
Net Profit After Tax ₹20.33 Cr ₹0.82 Cr 24.9x
Net Worth ₹115.99 Cr ₹5.67 Cr 20.5x
Earnings Per Share ₹2.16 ₹2.00 +8%

Comprehensive Platform Capabilities

Developed by wholly-owned subsidiary AVI AI Technologies Private Limited, Ashwini.tech is engineered specifically for India's mobile-first generation. The platform features six integrated instruments including The Reader for OCR and clinical extraction, The Timeline for source-linked medical history, Explain My Lab for plain-English explanations, Medication Brain for adherence tracking, Doctor Pack for printable visit summaries, and The Household for family profiles with role-aware caregiver access. The platform is currently live in private beta with conversational AI capabilities powered by Llama on Groq, providing sub-second responses with verifiable citations.

Platform Features Functionality
The Reader OCR + clinical extraction for English & Indian languages
The Timeline Chronological, source-linked medical history
Explain My Lab Plain-English explanations grounded in user trends
Medication Brain Schedules, adherence, refills tracking
Doctor Pack One-page printable visit summary
The Household Family profiles with role-aware caregiver access

Strategic Market Positioning

Ashwini.tech operates in the Personal Health Records (PHR) segment, positioned in the high stickiness, low competition quadrant of the market landscape. The platform leverages three key tailwinds: the Ayushman Bharat Digital Mission with 670 million+ ABHA accounts and 420 million+ records linked, 825 million+ internet users with sub-₹0.20/GB data costs, and the demographic opportunity of the sandwich generation aged 35-55 managing both parents and children. The company's zero-debt balance sheet and recent capital infusion provide flexibility for commercialization and ecosystem monetization in FY27.

Multi-Engine Revenue Strategy

The platform operates on a comprehensive revenue model with consumer subscriptions planned for general availability launch, NRI premium caregiving services targeting the diaspora market within 6-12 months, Doctor Pack channels for hospital and clinic OPD partnerships in Year 2, insurance white-label solutions and ABDM gateway services in Years 2-3, and pharma real-world evidence cohorts from Year 3 onwards. The same data layer feeds each revenue engine, enabling incremental revenue without incremental cost. The company maintains a risk-conscious design with a "no diagnosis, ever" pact, ensuring the platform serves as an information aid rather than clinical decision support.

Historical Stock Returns for AVI Polymers

1 Day5 Days1 Month6 Months1 Year5 Years
+4.96%+33.84%+24.99%+57.71%+44.65%+110.02%

How will AVI Polymers compete with established healthcare platforms like Practo and 1mg in the crowded Indian digital health market?

What regulatory challenges might Ashwini.tech face as it scales, particularly around data privacy and healthcare compliance in India?

Can AVI Polymers successfully monetize both AgriTech and HealthTech platforms simultaneously, or will resource allocation become a strategic challenge?

More News on AVI Polymers

1 Year Returns:+44.65%